Resultados de la búsqueda 61-70 of 14199 for mebendazole

1. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

   Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

3. Red de Atención Médica de Mayo Clinic

4. Mayo Clinic

   An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet. Feb. 24, 2018 . VID-20381066.

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...